Country Contribution to Investigators of Pivotal Clinical Trials and Their Primary Publications of New Drugs Approved by the US Food and Drug Administration, 2012–2021

Documenti analoghi

• The US Food and Drug Administration's Model‐Informed Drug Development Meeting Program: From Pilot to Pathway
  di: Rajanikanth Madabushi, et al.
  Pubblicazione: (2024)
• US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience
  di: Kimberly A. Smith, et al.
  Pubblicazione: (2025)
• Dose Determinations at Drug Approval Reviews: FDA‐Approved Drugs in Past 5 Years
  di: Sachiko Mita, et al.
  Pubblicazione: (2025)
• Trust in the Food and Drug Administration: A National Survey Study
  di: William B. Feldman, et al.
  Pubblicazione: (2024)
• Assessing Post‐Marketing Requirements for Orphan Drugs: A Cross‐Sectional Analysis of FDA and EMA Oversight
  di: Jae Hyeon Yu, et al.
  Pubblicazione: (2024)